Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
artificial antigen presenting cells
bioengineering
cancer
immunoengineering
immunotherapy
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
24 Feb 2021
24 Feb 2021
Historique:
pubmed:
13
2
2021
medline:
6
3
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Biomimetic biomaterials are being actively explored in the context of cancer immunotherapy because of their ability to directly engage the immune system to generate antitumor responses. Unlike cellular therapies, biomaterial-based immunotherapies can be precisely engineered to exhibit defined characteristics including biodegradability, physical size, and tuned surface presentation of immunomodulatory signals. In particular, modulating the interface between the biomaterial surface and the target biological cell is key to enabling biological functions. Synthetic artificial antigen presenting cells (aAPCs) are promising as a cancer immunotherapy but are limited in clinical translation by the requirement of
Identifiants
pubmed: 33573372
doi: 10.1021/acsami.0c19955
pmc: PMC8034558
mid: NIHMS1685757
doi:
Substances chimiques
Cations
0
Polymers
0
poly(beta-amino ester)
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7913-7923Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB029341
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007057
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA153952
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB028239
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA229042
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA130840
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA153952
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228133
Pays : United States
Références
J Immunother. 2015 Feb-Mar;38(2):54-61
pubmed: 25658614
Small. 2015 Apr;11(13):1519-25
pubmed: 25641795
Adv Drug Deliv Rev. 2017 May 15;114:102-115
pubmed: 28501510
ACS Nano. 2015 Jul 28;9(7):6861-71
pubmed: 26171764
ACS Nano. 2014 Mar 25;8(3):2252-60
pubmed: 24564881
Nat Biotechnol. 2018 Feb;36(2):160-169
pubmed: 29334370
Biomaterials. 2017 Feb;118:16-26
pubmed: 27940380
Biomaterials. 2014 Jan;35(1):269-277
pubmed: 24099710
PLoS One. 2012;7(2):e32398
pubmed: 22384241
J Immunol. 2012 Aug 1;189(3):1330-9
pubmed: 22732590
ACS Nano. 2017 Jun 27;11(6):5417-5429
pubmed: 28589725
Curr Protoc Immunol. 2001 May;Chapter 17:Unit 17.2
pubmed: 18432743
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4930-4
pubmed: 16549762
Nat Nanotechnol. 2014 Aug;9(8):639-47
pubmed: 25086604
J Control Release. 2012 Nov 28;164(1):41-8
pubmed: 23041278
Acta Biomater. 2016 Mar 1;32:24-34
pubmed: 26708710
Nano Lett. 2013;13(11):5608-14
pubmed: 24125583
Mol Ther. 2008 Apr;16(4):765-72
pubmed: 18334990
Trends Mol Med. 2005 Sep;11(9):412-20
pubmed: 16103011
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16028-33
pubmed: 15520369
Cancer Immunol Immunother. 2017 Sep;66(9):1229-1241
pubmed: 28501941
Trends Biotechnol. 2014 Apr;32(4):198-209
pubmed: 24630474
Nanomedicine. 2014 Jan;10(1):119-29
pubmed: 23891987
Nano Lett. 2017 Nov 8;17(11):7045-7054
pubmed: 28994285
J Immunol. 1992 Oct 1;149(7):2402-5
pubmed: 1527386
Acta Biomater. 2018 Mar 1;68:168-177
pubmed: 29292166
J Biol Chem. 2011 Oct 7;286(40):34883-92
pubmed: 21849500
J Biomed Biotechnol. 2012;2012:758102
pubmed: 23226945
Nat Med. 2016 Dec;22(12):1402-1410
pubmed: 27775706
Mol Pharm. 2008 Jul-Aug;5(4):516-26
pubmed: 18616278